---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-22-000040"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2022-07-01T23:59:59+00:00"
generated_at: "2026-06-24T21:47:05.138278+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Centessa board adds ex-BMS regulatory exec; director Kantoff resigns

## Summary
- Aaron Kantoff resigned from Centessa board effective July 1, 2022; no disagreement cited, will remain as advisor.
- Mathias Hukkelhoven, former SVP Global Regulatory at BMS, appointed to board and Nominating & Governance Committee.
- Hukkelhoven receives initial option for 96,000 ordinary shares vesting over 3 years, plus annual grants of 48,000 shares.
- Dr. Hukkelhoven also serves on Compugen (CGEN) board and as advisor to McKinsey and LianBio.

## SEC filing metadata
- accession: 0001847903-22-000040
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2022-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/cnta-20220701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-22-000040
- JSON: https://secwatch.observer/filing/0001847903-22-000040.json
- Plain text: https://secwatch.observer/filing/0001847903-22-000040.txt

## Key facts
- Executive change
  Mathias Hukkelhoven was appointed as director at Centessa Pharmaceuticals plc.
  - Action: appointed
  - Role: director
  source text: On July 1, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Mathias Hukkelhoven, Ph.D. to join the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm
- Executive change
  Aaron Kantoff resigned as director at Centessa Pharmaceuticals plc.
  - Action: resigned
  - Role: director
  source text: On July 1, 2022, Aaron Kantoff, a member of the board of directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company”) , notified the Company of his resignation from the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.